Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
Annals of Clinical and Translational Neurology, 2021 Objective Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP.
Yoshimi Enose‐Akahata +10 more
doaj +2 more sources
Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review [PDF]
Journal of the International AIDS Society, 2022 Globally about 1.7 million children were living with HIV in 2020. Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children.
Claire L Townsend +10 more
openalex +2 more sources
Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review. [PDF]
Basic Clin Pharmacol ToxicolABSTRACT Introduction Raltegravir, an HIV integrase inhibitor, although generally well tolerated, may cause severe reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS). This syndrome has been associated with impaired drug metabolism, viral reactivation and genetic factors including HLA‐B*53:01.
Ramos-Del Moral C +10 more
europepmc +2 more sources
Contemporary Antiretroviral Therapy Regimens in People With HIV Who Initiated Treatment in the Pre-Antiretroviral Therapy Era. [PDF]
J Med VirolJournal of Medical Virology, Volume 97, Issue 11, November 2025.
Adachi E +4 more
europepmc +2 more sources
Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo [PDF]
Frontiers in Pharmacology, 2019 Raltegravir, an inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, has been used to treat HIV/acquired immunodeficiency syndrome; however, its therapeutic effects on pulmonary fibrosis have not been investigated.
Xue Zhang +5 more
openalex +2 more sources
In Vitro and Clinical Evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-Mediated Drug-Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor. [PDF]
J Clin PharmacolAbstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Schueller O +4 more
europepmc +2 more sources
Cancers, 2021 Simple Summary Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. Serrated adenocarcinoma (SAC) has been recently recognized by the WHO as a histological CRC with bad prognosis.
Begoña Alburquerque-González +14 more
semanticscholar +1 more source
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. [PDF]
PLoS ONE, 2009 Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in ...
Aylin Yilmaz +6 more
doaj +1 more source
Journal of Antimicrobial Chemotherapy, 2021 OBJECTIVES The second-generation integrase strand transfer inhibitor (INSTI) bictegravir is becoming accessible in low- and middle-income countries (LMICs), and another INSTI, cabotegravir, has recently been approved as a long-acting injectable.
E. Ndashimye +10 more
semanticscholar +1 more source